High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO2-Au Nanocomposite

Zheng, Wei; Cai, Xiaoping; Zhang, Junping; Fan, Junming; Xu, Jiangyan; Xu, Liran

doi:10.3390/molecules24040656

“…Therefore, NSE is generally considered a diagnostic and therapeutic marker of SCLC(26). ProGRP is composed of three isoforms expressed at the mRNA level and is the neuropeptide gastrin-releasing peptide produced in SCLC cells (27). Besides, serum ProGRP elevations are speci c to SCLCs, pulmonary carcinoid tumors, and several types of neuroendocrine tumors(28).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer

Chen

¹

,

Kuang

²

,

Wang

³

et al. 2022

Preprint

0

View full text Add to dashboard Cite

Background: Tumor markers CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag were routinely used for lung cancer. The objective of this study was to evaluate the diagnostic and prognostic value of these markers.Methods: The levels of 5 serum tumor markers were measured in 255 patients with lung cancer (44 squamous cell carcinoma, 183 adenocarcinoma, 28 small cell lung cancer), 103 patients with benign lung disease, and 120 healthy controls. The relevant clinical data of the patients were collected to analyze the expression of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the serum of lung cancer and their correlation with prognosis.Results: The positive rates and expression levels of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the lung cancer group were higher than those in patients with benign lung diseases and healthy controls. CYFRA21-1 and SCC-Ag were highly expressed in lung squamous cell carcinoma, and NSE and proGRP were highly expressed in small cell lung cancer. The expression levels of CYFRA 21-1, NSE, and proGRP in small cell lung cancer were higher than those in non-small cell lung cancer. The levels of CEA, CYFARA21-1, NSE, and proGRP were linearly correlated with the occurrence of lung cancer, while the level of SCC-Ag was not significantly correlated with the occurrence of lung cancer. What’s more, the levels of CYFAR21-1 and NSE in the death group of lung cancer patients were higher than those in the survival group.Conclusion: CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag played a good role in diagnosing lung cancer. CYFRA21-1 and SCC-Ag can be used as markers for the diagnosis of squamous cell carcinoma, and NSE and proGRP can be used as markers for small cell lung cancer. Meanwhile, the combined detection of CEA, CYFARA21-1, NSE, and proGRP had the highest diagnostic accuracy for lung cancer. Furthermore, CYFAR21-1 and NSE can be used to evaluate the prognosis of lung cancer patients.

show abstract

“…Therefore, NSE is generally considered a diagnostic and therapeutic marker of SCLC(26). ProGRP is composed of three isoforms expressed at the mRNA level and is the neuropeptide gastrinreleasing peptide produced in SCLC cells (27). Besides, serum ProGRP elevations are speci c to SCLCs, pulmonary carcinoid tumors, and several types of neuroendocrine tumors(28).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients with Lung Cancer

Chen

¹

,

Kuang

²

,

Wang

³

et al. 2021

Preprint

0

View full text Add to dashboard Cite

Background: Tumor markers CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag were routinely used for lung cancer. The objective of this study was to evaluate the diagnostic and prognostic value of these markers.Methods: The levels of 5 serum tumor markers were measured in 255 patients with lung cancer (44 squamous cell carcinoma, 183 adenocarcinoma, 28 small cell lung cancer), 103 patients with benign lung disease, and 120 healthy controls. The relevant clinical data of the patients were collected to analyze the expression of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the serum of lung cancer and their correlation with prognosis.Results: The positive rates and expression levels of CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag in the lung cancer group were higher than those in patients with benign lung diseases and healthy controls. CYFRA21-1 and SCC-Ag were highly expressed in lung squamous cell carcinoma, and NSE and proGRP were highly expressed in small cell lung cancer. The expression levels of CYFRA 21-1, NSE, and proGRP in small cell lung cancer were higher than those in non-small cell lung cancer. The levels of CEA, CYFARA21-1, NSE, and proGRP were linearly correlated with the occurrence of lung cancer, while the level of SCC-Ag was not significantly correlated with the occurrence of lung cancer. What’s more, the levels of CYFAR21-1 and NSE in the death group of lung cancer patients were higher than those in the survival group.Conclusion: CEA, CYFRA21-1, NSE, proGRP, and SCC-Ag played a good role in diagnosing lung cancer. CYFRA21-1 and SCC-Ag can be used as markers for the diagnosis of squamous cell carcinoma, and NSE and proGRP can be used as markers for small cell lung cancer. Meanwhile, the combined detection of CEA, CYFARA21-1, NSE, and proGRP had the highest diagnostic accuracy for lung cancer. Furthermore, CYFAR21-1 and NSE can be used to evaluate the prognosis of lung cancer patients.

show abstract

“…( b ) Schematic diagram of an electrochemical immunosensor structure. Reprinted with permission from [ 38 ]. ( c ) Schematic of a biofunctionalized black phosphorus-based fiber optic biosensor.…”

Section: Application Of Biosensor In Detection Of Tumor Biomarkersmentioning

confidence: 99%

Recent Progress in Biosensors for Detection of Tumor Biomarkers

Li

¹

,

Jiang

²

,

Xue

³

et al. 2022

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide, with an increasing mortality rate over the past years. The early detection of cancer contributes to early diagnosis and subsequent treatment. How to detect early cancer has become one of the hot research directions of cancer. Tumor biomarkers, biochemical parameters for reflecting cancer occurrence and progression have caused much attention in cancer early detection. Due to high sensitivity, convenience and low cost, biosensors have been largely developed to detect tumor biomarkers. This review describes the application of various biosensors in detecting tumor markers. Firstly, several typical tumor makers, such as neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), squamous cell carcinoma antigen (SCCA), carbohydrate, antigen19-9 (CA19-9) and tumor suppressor p53 (TP53), which may be helpful for early cancer detection in the clinic, are briefly described. Then, various biosensors, mainly focusing on electrochemical biosensors, optical biosensors, photoelectrochemical biosensors, piezoelectric biosensors and aptamer sensors, are discussed. Specifically, the operation principles of biosensors, nanomaterials used in biosensors and the application of biosensors in tumor marker detection have been comprehensively reviewed and provided. Lastly, the challenges and prospects for developing effective biosensors for early cancer diagnosis are discussed.

show abstract

High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO2-Au Nanocomposite

Cited by 15 publications

References 38 publications

Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer

Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer

Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients with Lung Cancer

Recent Progress in Biosensors for Detection of Tumor Biomarkers

Contact Info

Product

Resources

About